RemSleep Holdings Inc. develops the DeltaWave CPAP mask system, a niche device with FDA clearance that recently began commercial sales. Following founder Thomas Wood’s death in early 2026, new leadership has stepped in to guide the company through initial commercialization challenges. The company has seen a sharp decline in revenue over the last fiscal year despite earlier higher sales, while operating losses have widened substantially. Liquidity remains constrained with a sub-1 current ratio and ongoing negative cash flow from operations. Going forward, success hinges on expanding market reach through new FDA applications, distributor partnerships, and institutional accounts under the new CEO’s commercial strategy.